Ann Lab Med.  2017 Mar;37(2):174-176. 10.3343/alm.2017.37.2.174.

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria

• Gonzalez M
• McMullen A
• Wallace MA
• Crotty MP
• Ritchie DJ
• Burnham CA

• KMID: 2373640
• DOI: http://doi.org/10.3343/alm.2017.37.2.174

Abstract

No abstract available.

MeSH Terms

Anti-Bacterial Agents/*pharmacology
Azabicyclo Compounds/*pharmacology
Bacterial Proteins/genetics
Ceftazidime/*pharmacology
Cephalosporins/*pharmacology
DNA, Bacterial/genetics/metabolism
Drug Resistance, Bacterial/*drug effects
Gram-Negative Bacteria/drug effects/*isolation & purification
Humans
Microbial Sensitivity Tests
Penicillanic Acid/*analogs & derivatives/pharmacology
Pseudomonas aeruginosa/drug effects/isolation & purification
Real-Time Polymerase Chain Reaction
Anti-Bacterial Agents
Azabicyclo Compounds
Bacterial Proteins
Ceftazidime
Cephalosporins
DNA, Bacterial
Penicillanic Acid

Reference

1. Estabrook M, Bussell B, Clugston SL, Bush K. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases. J Clin Microbiol. 2014; 52:4049–4052. PMID: 25143578.

2. Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ, Jones RN. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015; 59:3656–3659. PMID: 25845861.

3. Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016; 60:3227–3231. PMID: 26976862.

4. Doern CD, Dunne WM Jr, Burnham CA. Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods. J Clin Microbiol. 2011; 49:1143–1147. PMID: 21209164.

5. Centers for Disease Control and Prevention. Multiplex real-time PCR detection of Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM-1). 2010. http://www.cdc.gov/hai/pdfs/labsettings/kpc-ndm-protocol-2011.pdf.

6. Manji R, Bythrow M, Branda JA, Burnham CA, Ferraro MJ, Garner OB, et al. Multi-center evaluation of the Vitek® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 2014; 33:337–346. PMID: 24019163.

7. Richter SS, Sercia L, Branda JA, Burnham CA, Bythrow M, Ferraro MJ, et al. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the Vitek MS system. Eur J Clin Microbiol Infect Dis. 2013; 32:1571–1578. PMID: 23818163.

8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 25th Informational supplement, M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute;2015.

9. Sucher AJ, Chahine EB, Cogan P, Fete M. Ceftolozane/tazobactam: A new cephalosporin and β-lactamase inhibitor combination. Ann Pharmacother. 2015; 49:1046–1056. PMID: 26160970.